Journal of Leukemia
Open Access
ISSN: 2329-6917
ISSN: 2329-6917
Yasser R Abou Mourad
MD, FRCPC, Gordon & Leslie Diamond Health Care Center, Division of Hematology,
Room 10149, 10th floor 2775 Laurel Street, Vancouver, BC, Canada V5Z 1M9
Canada
Research Article
High Induction Response Rate, but Poor Long-Term Disease Free Survival in Elderly Patients Treated Aggressively for Acute Lymphoblastic Leukemia
Author(s): Adisak Tantiworawit, Walaa A Rajkhan, Michael J Barnett, John D Shepherd, Alina S Gerrie, Raewyn Broady, Donna L Forrest, Donna E Hogge, Stephen H Nantel, Sujaatha Narayanan, Thomas J Nevill, Maryse M Power, Heather J Sutherland, Cynthia L Toze, Kevin W Song and Yasser R Abou MouradAdisak Tantiworawit, Walaa A Rajkhan, Michael J Barnett, John D Shepherd, Alina S Gerrie, Raewyn Broady, Donna L Forrest, Donna E Hogge, Stephen H Nantel, Sujaatha Narayanan, Thomas J Nevill, Maryse M Power, Heather J Sutherland, Cynthia L Toze, Kevin W Song and Yasser R Abou Mourad
Elderly Acute Lymphoblastic Leukemia (ALL) patients are routinely offered palliative chemotherapy and best supportive care. Few studies have addressed their outcome with aggressive chemotherapy. We pursued this population based study to address the outcome of ALL patients older than 60 years treated with aggressive chemotherapy. We reviewed 32 consecutive patients treated with aggressive chemotherapy between 1989 and 2008. Twenty-seven patients (84.4%) achieved Complete Remission (CR) to induction chemotherapy of whom 23 patients (85.2%) had disease relapse. Median time to relapse was 8 (3.7-44) months. Median disease free survival and overall survival were 10.4 (0-43.9) and 16.3 (1.3-59) months, respectively. Cause of death was disease progression in 25/27 (92.6%). Seven patients (21.8%) had Philadelphia chromosome positive (Ph+) disease. Six out of these seven patients received combina.. View More»
DOI:
10.4172/2329-6917.1000163